ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

OXB Oxford Biomedica Plc

368.00
19.50 (5.60%)
26 Jul 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Oxford Biomedica Plc LSE:OXB London Ordinary Share GB00BDFBVT43 ORD 50P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  19.50 5.60% 368.00 367.00 370.50 368.00 347.50 348.50 437,399 16:29:58
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Medicinal Chems,botanicl Pds 89.54M -184.16M -1.8414 -2.00 348.55M
Oxford Biomedica Plc is listed in the Medicinal Chems,botanicl Pds sector of the London Stock Exchange with ticker OXB. The last closing price for Oxford Biomedica was 348.50p. Over the last year, Oxford Biomedica shares have traded in a share price range of 164.40p to 460.00p.

Oxford Biomedica currently has 100,013,988 shares in issue. The market capitalisation of Oxford Biomedica is £348.55 million. Oxford Biomedica has a price to earnings ratio (PE ratio) of -2.00.

Oxford Biomedica Share Discussion Threads

Showing 27326 to 27349 of 27350 messages
Chat Pages: 1094  1093  1092  1091  1090  1089  1088  1087  1086  1085  1084  1083  Older
DateSubjectAuthorDiscuss
26/7/2024
20:35
BMS chooses Car T over Bispecific in MM
marcusl2
26/7/2024
16:23
I would say it's either a coincidence or that they are up to something which some people have twigged.

They don't need money and if it was a fundraising the price would be going the other way.

Takeover brewing is really unlikely as we have some big holders who collectively own more than half.

Malaria is the obvious guess, but that has been hovering for so long now.

The CAR-T news they have already basically told us all but the names and the size.

Something else?

harry s truman
26/7/2024
16:16
Harry, is that a usual occurrence in your view :)
takeiteasy
26/7/2024
16:12
OXB's website down too?
harry s truman
26/7/2024
14:47
... within 4 months
dr darkstar
26/7/2024
14:44
Projections on this breakout are 480 then 600 ( give or take 10)
dr darkstar
26/7/2024
14:41
Or (slightly more cynically) we are about to find out why none of the insiders could buy after the results but the boys in the market have already heard something.
harry s truman
26/7/2024
14:32
Last time the market was very kind here allowing everyone to get in around the time of the results and run with the upslope charting wise - this time they are leading the share price upwards prior to the release of any new information which means the nervous/less decided here will have to keep waiting until much may be baked into the share price Who said share trading was ever fair :)

nai etc

takeiteasy
26/7/2024
14:24
I will second that Connello.

On the secret level 2 page (click this link then press the "Today" bar in the chart, then scroll to the bottom of the page) I can't remember it looking like that before.

It needs a student of the black arts to explain.

harry s truman
26/7/2024
14:08
There was a time circa September/October 2023 where the price continued to move up to 530 without any news. The trend was our friend.

Unfortunately a seller appeared & put an end to that.

Hopefully on this occasion we will have our long awaited news/Update to support the increasing share price

connello
26/7/2024
11:06
Active again. 11th month high
mirabeau
26/7/2024
10:47
With my glass half full hat it's only a month since the board assured investors at the AGM that it was all on track and going well. I'm sure Frank thinks that's all we need to know - i.e. his full year results presentation was incredibly positive and he's said it's still on target.

However, and as you note, when he previously made the point that we are going away from reporting individual contract wins (as per my example today of the pre-interims period last year), then this running total KPI table was promised in lieu and we have yet to see it - which I still think is an easy win for them which for some reason they are choosing not to do.

Why? Well there are many possibilities and maybe most likely is that they decided 3 months post FY results (29th April) would be the day - which as Phil notes is Monday.

As I type the volume has gone mad and the price is up, so maybe an indication there that a RNS is in the works?

harry s truman
26/7/2024
09:39
A reminder of the response from OXB about more regular reporting and that they would update the market 'between now and September'. No I am none the wiser either.
seanje
26/7/2024
09:15
So I guess it’s Monday, or not at all and we wait for the interims?
philh75
26/7/2024
09:15
Wearing my stuck record hat, I'd once again point out that the volume today (just over 3k in the first hour) indicates that there is nothing out there at the moment (good or bad) to drive it, meaning that any price movements aren't really going to tell us anything.

I think on the upside it does tell us that there is no institutional seller out there at the moment dripping out a sale, so that's my glass half full take - but overall OXB haven't done much of anything of late to stimulate that interest with news.

I hope for news every day, but my expectation is a different kettle of fish. I think if we get to Wednesday next week (end of July of course) without the quarterly business update with promised KPI table, then they will just run until the interims at the end of September.

If you look back to last year then we had nothing at all between the FY results presentation and the interim results presentation apart from the extension RNS with Cabaletta at the end of August. That was a great deal and good to see, but to the outside world that was all OXB had won since the FY results.

At the interims they told us that in the first 6 months they had gone from 18 partners and 30 programmes to 24 clients and 41 programmes.

So 8 new clients which they didn't / couldn't mention until the interims and another 11 programmes including the extension to Cabaletta.

It was very positive but they chose to keep quiet about it until the results. If they did the same again this September then it wouldn't surprise me at all.

harry s truman
25/7/2024
16:10
Pity CFC1 is no longer posting as "Blue is the colour".
gareth jones
25/7/2024
15:54
There's not much blue around today so it should get noticed.
boadicea
25/7/2024
15:24
Looking good. Onwards upwards.
kumala
25/7/2024
15:23
breaking to the upside
mirabeau
25/7/2024
14:28
It's easy to forget these have more than doubled from their lows. The share price was always going to need to form structure, this is a good thing, and when we get the catalyst 420s should be the next level.
rathean
25/7/2024
12:50
I have to say, when i initially saw there ware 2 RNS's this morning, prior to reading, my heart lept, i thought this is the big one. Who would be a trader eh. Love it!!!!!
jezmundo
25/7/2024
11:54
7,890 shares traded as I type.

We have seen the previous explanation of their new policy re not announcing new contracts unless it's unavoidable (i.e. they are large enough to change guidance and / or the client specifically wants to), but this policy of running silent could well be the biggest factor in the seeming disinterest from the market.

So as of today IM have their rep watching their investment as a non-exec just like Novo have theirs, which is great for Novo and IM as they get regular briefings from Roch.

We have something from IR at OXB saying that they definitely might be intending to report quarterly with the KPI table at some point, even though you won't find anything that binding in the official OXB presentations.

I'm not for a minute here suggesting that they are avoiding reporting for negative reasons, as bizarrely all available evidence seems to point to the contrary, but busy or not they should have put the table out with the state of play.

harry s truman
24/7/2024
21:22
It is a good article and a nice mention of T-Charge too.

Just a reminder though that whilst our LentiVector is the tool used to alter the T-Cells in a lot of CAR-T treatments in various stages of development, it's far from the only use for LentiVector.

On my little list we are partnered with at least 7 CAR-T companies, two of which are Novartis (commercial) and another we are about to learn the name of as it goes commercial, but I think it's important to note that we had 35 partners back in April with 5 late stage programmes. There will be a lot of non CAR-T work in the remainder of those 35+ partners.

harry s truman
24/7/2024
20:36
Excellent article, many thanks
pharmaboy3
Chat Pages: 1094  1093  1092  1091  1090  1089  1088  1087  1086  1085  1084  1083  Older

Your Recent History

Delayed Upgrade Clock